Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144391 · ClinicalTrials.gov registry record · Phase 4
Testosterone Gel Applied to Women With Pituitary Gland Problems
A Phase 4 study of Panhypopituitarism, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00144391: Completed Phase 4 study of Panhypopituitarism, sponsored by Charles Drew University of Medicine and Science.
NCT00144391 is a Phase 4 study of Panhypopituitarism that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00144391, a Phase 4 study of Panhypopituitarism, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The principal aim of this study is to evaluate if application of testosterone gel leads to improvement in measures of sexual function, thinking ability and quality of life in women with dysfunction of the pituitary gland. A secondary purpose is to determine the effects of testosterone replacement on body composition and muscle function and strength.
Primary Outcome
change in fatigue impact scale there are 42 questions. Each question can be answered from 0 (no problem) to 4 (extreme problem), so a higher score indicates more severe fatigue impact. minimum score=0, maximum score =148 values are calculated at baseline and 6 months and the score at 6 months compared to baseline months is calculated
Conditions Studied
Interventions
- DRUG Transdermal Testosterone gel
Study Locations (1)
California
- Charles Drew University of Medicine and Science - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
What the finished NCT00144391 record still lists
NCT00144391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Panhypopituitarism appearing as the primary indexed condition, and to 1 intervention - of which Transdermal Testosterone gel is the first listed.
NCT00144391 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00144391 about?
NCT00144391 is a clinical study titled "Testosterone Gel Applied to Women With Pituitary Gland Problems". The principal aim of this study is to evaluate if application of testosterone gel leads to improvement in measures of sexual function, thinking ability and quality of life in women with dysfunction of the pituitary gland. A secondary purpose is to determine the effects of testosterone replacement on...
What is the current status of trial NCT00144391?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2003-07. Estimated completion is 2010-12.
What conditions does trial NCT00144391 study?
This clinical trial studies the following conditions: Panhypopituitarism.
What interventions are being tested in trial NCT00144391?
The interventions under investigation include: Transdermal Testosterone gel (DRUG).
Who is sponsoring clinical trial NCT00144391?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00144391 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Panhypopituitarism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00144391's enrollment target sits among peer trials
20 1753rd of 2000 higher than 168 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia